Dr. Green is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
- University of Virginia Medical CenterResidency, Internal Medicine, 1995 - 1998
- University of Texas Medical Branch School of MedicineClass of 1995
Certifications & Licensure
- TX State Medical License 2000 - 2024
- MA State Medical License 1981 - 2017
Clinical Trials
- CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer Start of enrollment: 2005 Dec 01
Publications & Presentations
PubMed
- 24 citationsRadiation dose escalation for loco-regional recurrence of breast cancer after mastectomyHeath D. Skinner, Eric A. Strom, S.B. Motwani, Wendy A. Woodward, Marjorie C. Green
Radiation Oncology. 2013-01-11 - 3161 citationsTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe C. Yuen
Nature. 2018-02-22 - 675 citationsAtezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3,...Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott
Lancet. 2019-06-15
Press Mentions
- Moderna and MSD Begin Trial of mRNA-4157 and Keytruda Combination for Lung CancerOctober 29th, 2024
- Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 TrialSeptember 17th, 2024
- Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 TrialSeptember 7th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: